Osteomalacia Medical Services in China

Osteomalacia is a metabolic bone disorder characterized by inadequate mineralization of newly synthesized osteoid matrix, resulting in soft, weak, and structurally compromised bones. Unlike osteoporosis—which involves reduced bone mass but normal mineralization—osteomalacia reflects a defect in the bone mineralization process itself, primarily due to severe and prolonged deficiency of vitamin D, impaired vitamin D metabolism, or disturbances in phosphate homeostasis. Pathogenically, the condition arises when serum calcium, phosphorus, or active vitamin D (calcitriol) levels fall below thresholds required for hydroxyapatite crystal deposition in the organic bone matrix. Common underlying mechanisms include nutritional vitamin D deficiency (especially in elderly, housebound, or dark-skinned individuals with limited sun exposure), gastrointestinal malabsorption (e.g., celiac disease, post-bariatric surgery), chronic kidney disease (reducing 1α-hydroxylase activity), hereditary disorders like X-linked hypophosphatemia, or drug-induced causes (e.g., anticonvulsants that accelerate vitamin D catabolism). Epidemiologically, osteomalacia is relatively rare in healthy adults in high-income countries but remains underdiagnosed—particularly among older adults, postmenopausal women, and immigrant populations with cultural sun-avoidance practices or dietary restrictions. In China, prevalence is higher in northern regions with lower UVB exposure and among institutionalized elderly; population-based studies estimate clinical osteomalacia affects ~0.1–0.5% of adults over 60, though subclinical biochemical abnormalities may be present in up to 20% of community-dwelling seniors. Key risk factors include chronic kidney disease, gastrointestinal resection or inflammatory bowel disease, obesity (vitamin D sequestration in adipose tissue), prolonged antiepileptic therapy, and exclusive breastfeeding without vitamin D supplementation in infants. Clinically, patients present with diffuse bone pain (especially in pelvis, thighs, and lower back), proximal muscle weakness leading to waddling gait and difficulty rising from chairs or climbing stairs, and increased fracture risk—even without trauma. Hypocalcemia may cause tetany, paresthesias, or seizures in severe cases. Quality of life is significantly impaired: chronic pain limits mobility and independence, fatigue and muscle weakness reduce capacity for daily activities and employment, and fear of falling contributes to social isolation and depression. Untreated osteomalacia increases long-term morbidity—including vertebral compression fractures, pelvic deformities (e.g., Looser’s zones), and secondary hyperparathyroidism—and elevates all-cause mortality in elderly cohorts. Early diagnosis via serum 25(OH)D, calcium, phosphate, alkaline phosphatase, PTH, and bone-specific imaging (e.g., DXA with trabecular bone score, or bone biopsy in atypical cases) is essential. Management focuses on correcting the underlying etiology while restoring mineral balance through targeted supplementation and lifestyle intervention.

Osteomalacia is a metabolic bone disorder characterized by defective bone mineralization, resulting in accumulation of unmineralized osteoid matrix and consequent bone softening, pain, proximal muscle weakness, and increased fracture risk. While often grouped with osteoporosis clinically, osteomalacia reflects a distinct pathophysiology rooted in impaired hydroxyapatite deposition—primarily due to chronic hypophosphatemia and/or vitamin D deficiency or resistance. In the context of Rheumatology and Immunology (Rheumatology & Immunology Department), osteomalacia frequently arises from immune-mediated or inflammatory mechanisms, drug-induced effects, or paraneoplastic syndromes, rather than isolated nutritional insufficiency.

Common causes include profound vitamin D deficiency—most frequently from inadequate cutaneous synthesis (e.g., chronic sun avoidance, dark skin pigmentation in high-latitude regions, institutionalization), malabsorption syndromes (e.g., celiac disease, Crohn’s disease, post-gastric bypass states), or hepatic/renal dysfunction impairing vitamin D activation (25-hydroxylation in liver; 1α-hydroxylation in kidney). Hypophosphatemic osteomalacia is equally prevalent and may stem from renal phosphate wasting, as seen in X-linked hypophosphatemia (XLH), tumor-induced osteomalacia (TIO)—a paraneoplastic condition caused by phosphaturic mesenchymal tumors secreting FGF23—or autoimmune tubulointerstitial nephritis affecting proximal tubular reabsorption. Notably, TIO is a key diagnostic consideration in adult-onset, progressive osteomalacia with otherwise unexplained hypophosphatemia and elevated FGF23; it mandates thorough imaging for occult mesenchymal tumors.

Triggers encompass acute exacerbations of underlying conditions: initiation of antiepileptic drugs (e.g., phenytoin, carbamazepine) that induce CYP450-mediated vitamin D catabolism; prolonged glucocorticoid therapy impairing intestinal calcium absorption and osteoblast function; rapid correction of acidosis in chronic kidney disease leading to transient hypophosphatemia; or abrupt dietary restriction in patients with preexisting malabsorption. Immune checkpoint inhibitors (e.g., anti-CTLA-4, anti-PD-1 agents) have emerged as novel triggers via induction of autoimmune tubulointerstitial nephritis or granulomatous inflammation causing dysregulated vitamin D metabolism.

Risk factors are multifactorial. Advanced age increases susceptibility due to reduced skin 7-dehydrocholesterol, diminished renal 1α-hydroxylase activity, decreased dietary intake, and polypharmacy. Female sex confers higher risk, particularly in postmenopausal women with concomitant osteoporosis and vitamin D insufficiency. Chronic inflammatory rheumatic diseases—including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and ankylosing spondylitis—are associated with both vitamin D deficiency (due to photosensitivity, reduced outdoor activity, and chronic inflammation suppressing 1α-hydroxylase) and direct bone toxicity from cytokines (e.g., TNF-α, IL-6, RANKL). Patients on long-term proton pump inhibitors (PPIs) face elevated risk due to gastric acid suppression impairing calcium solubilization and possibly altering gut microbiota involved in vitamin D metabolism.

Genetic factors play a pivotal role in hereditary forms. X-linked hypophosphatemia (XLH), caused by loss-of-function mutations in PHEX, leads to FGF23 excess and renal phosphate wasting. Autosomal dominant hypophosphatemic rickets (ADHR) results from gain-of-function FGF23 mutations resistant to proteolytic cleavage. Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) stems from SLC34A3 mutations impairing renal phosphate reabsorption. Rare autosomal recessive disorders include vitamin D-dependent rickets type 1A (CYP27B1 mutations) and type 2A (VDR mutations), both presenting in childhood but occasionally unmasked in adulthood under physiological stress.

Environmental factors include geographic location (latitude >35° north/south limits UVB exposure October–March), air pollution (reducing ambient UV radiation), cultural practices involving full-body clothing or strict indoor lifestyles, occupational sun deprivation (e.g., night-shift workers, office-based professionals), and dietary patterns low in vitamin D–rich foods (fatty fish, fortified dairy) and high in phytates or aluminum-containing antacids (which bind phosphate). Urban living, sedentary behavior, obesity (adipose sequestration of vitamin D), and socioeconomic disadvantage limiting access to nutritious food or healthcare further compound risk. Importantly, in rheumatologic practice, environmental triggers often interact synergistically with immune dysregulation—e.g., vitamin D deficiency exacerbating Th17 polarization in RA, thereby creating a vicious cycle of inflammation and bone demineralization.

Osteomalacia is a metabolic bone disorder characterized by defective bone mineralization due to impaired hydroxyapatite deposition in the osteoid matrix, most commonly resulting from chronic vitamin D deficiency, disorders of vitamin D metabolism (e.g., hepatic or renal dysfunction), or abnormalities in phosphate homeostasis (e.g., tumor-induced osteomalacia, hereditary hypophosphatemic rickets). Although classically associated with endocrinology or nephrology, osteomalacia frequently presents to rheumatology and immunology departments—particularly in the context of autoimmune polyglandular syndromes, chronic inflammatory rheumatic diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus) complicated by malabsorption or corticosteroid-induced bone loss, or when overlapping with conditions such as antiphospholipid syndrome-associated renal tubular dysfunction. Early symptoms are often insidious and nonspecific, frequently misattributed to aging, deconditioning, or fibromyalgia. Patients may report persistent, diffuse musculoskeletal fatigue, generalized weakness (especially proximal myopathy), and vague, poorly localized bone discomfort—most commonly in the pelvis, lower back, and thighs. A hallmark early feature is progressive difficulty rising from chairs or climbing stairs due to symmetric proximal muscle weakness, reflecting underlying myopathy secondary to hypophosphatemia and impaired mitochondrial energy metabolism in skeletal muscle. Early gait changes—including a waddling pattern—may emerge before overt pain or radiographic findings. Patients may also experience nocturnal leg cramps, paresthesias (due to associated hypocalcemia or chronic nerve irritation), and subtle reductions in exercise tolerance. These prodromal manifestations typically evolve over months to years. Typical symptoms become more pronounced as mineralization failure progresses. Diffuse, deep, aching bone pain—often described as 'boring' or 'gnawing'—predominates in weight-bearing regions: lumbar spine, pelvis (sacroiliac joints and pubic rami), hips, and proximal femora. Pain is typically bilateral, worsens with mechanical loading, and fails to respond adequately to conventional analgesics. Skeletal deformities may develop, including pelvic flattening (coxa vara), bowing of the femora or tibiae, and vertebral compression leading to height loss and dorsal kyphosis. Pathologic fractures—particularly insufficiency fractures of the pubic rami, femoral neck, or sacrum—are common and may occur with minimal or no trauma; these are often radiographically subtle on initial plain films but highly suggestive when identified in at-risk patients. Muscle involvement remains prominent: objective proximal muscle weakness (e.g., inability to maintain squat position for >10 seconds, positive Gowers’ sign), reduced grip strength, and diminished deep tendon reflexes (especially patellar and Achilles) reflect both myopathic and neurogenic components. Accompanying symptoms frequently reflect underlying etiology or systemic sequelae. Hypocalcemia may manifest as perioral or acral paresthesias, carpopedal spasm, laryngospasm, or seizures—though overt tetany is less common than in acute hypocalcemia. Hypophosphatemia contributes to cognitive fog, irritability, and depression. In patients with gastrointestinal etiologies (e.g., celiac disease, post-bariatric surgery), concomitant diarrhea, steatorrhea, or iron-deficiency anemia may be present. Those with renal phosphate wasting may exhibit polyuria, polydipsia, or nephrocalcinosis-related flank pain. Chronic inflammation-related osteomalacia may coexist with arthralgias, morning stiffness, or extra-articular manifestations (e.g., sicca symptoms, Raynaud’s phenomenon). Complications arise from prolonged demineralization and biomechanical compromise. Recurrent low-trauma fractures increase morbidity and risk of long-term disability, particularly hip fractures in older adults. Vertebral collapse can lead to restrictive lung disease, constipation, and abdominal discomfort. Severe proximal myopathy predisposes to falls and immobility-related complications—including venous thromboembolism, pressure ulcers, and pneumonia. Cardiac complications include left ventricular hypertrophy and arrhythmias secondary to chronic electrolyte disturbances. In children (when presenting as rickets), growth retardation, dental enamel hypoplasia, and craniosynostosis may occur—but this age group falls outside the typical rheumatology referral scope. Diagnosis requires integration of clinical suspicion, biochemical profiling, and imaging. First-line laboratory evaluation includes serum calcium (often low-normal or low), phosphate (typically low), alkaline phosphatase (markedly elevated—especially bone-specific isoform), 25-hydroxyvitamin D (usually <20 ng/mL), parathyroid hormone (elevated in secondary hyperparathyroidism), creatinine, estimated glomerular filtration rate, and urinary phosphate excretion (e.g., TmP/GFR). Serum fibroblast growth factor 23 (FGF23) is critical in suspected tumor-induced osteomalacia or hereditary forms. Radiography reveals characteristic features: pseudofractures (Looser zones)—transverse lucent lines perpendicular to bone cortex, most commonly at medial femoral neck, pubic rami, scapulae, and ribs—and generalized osteopenia. Dual-energy X-ray absorptiometry (DXA) shows low bone mineral density but cannot distinguish osteomalacia from osteoporosis; thus, it is supportive but not diagnostic. Bone biopsy with undecalcified histomorphometry remains the gold standard, demonstrating increased osteoid volume, prolonged mineralization lag time, and widened osteoid seams (>20 µm). MRI may detect active pseudofractures as bone marrow edema; CT is useful for detecting subtle Looser zones or occult tumors in FGF23-mediated disease. Differential diagnosis is essential to avoid mismanagement. Osteoporosis shares features of low BMD and fragility fractures but lacks elevated alkaline phosphatase, pseudofractures, and myopathy; bone turnover markers are typically normal or low. Paget’s disease exhibits markedly elevated alkaline phosphatase but demonstrates mosaic bone pattern on histology, cortical thickening, and asymmetric deformities—not pseudofractures. Metastatic bone disease causes lytic or blastic lesions with abnormal serum tumor markers and often elevated calcium. Multiple myeloma presents with monoclonal gammopathy, renal impairment, anemia, and punched-out lytic lesions—not Looser zones. Fibromyalgia mimics early fatigue and diffuse pain but lacks objective weakness, biochemical abnormalities, or radiographic findings. Chronic kidney disease–mineral and bone disorder (CKD-MBD) overlaps significantly but must be distinguished by eGFR, intact PTH, and FGF23 levels; in advanced CKD, 1,25-dihydroxyvitamin D is low despite preserved 25-OHD. Finally, hypophosphatasia—a rare genetic disorder—presents with low alkaline phosphatase (not elevated), dental abnormalities, and premature tooth loss, distinguishing it from classic osteomalacia.

Osteomalacia is a metabolic bone disorder characterized by defective bone mineralization, resulting in soft, weak bones due to inadequate hydroxyapatite deposition in the osteoid matrix. Unlike osteoporosis—which involves reduced bone mass with normal mineralization—osteomalacia reflects a qualitative defect in bone mineralization, most commonly attributable to chronic vitamin D deficiency, impaired vitamin D metabolism (e.g., hepatic or renal disease), hereditary disorders of phosphate handling (e.g., X-linked hypophosphatemia), or malabsorption syndromes. In the Department of Rheumatology and Immunology, osteomalacia is frequently evaluated alongside other systemic musculoskeletal and autoimmune conditions—such as rheumatoid arthritis, systemic lupus erythematosus, or antiphospholipid syndrome—where chronic inflammation, glucocorticoid use, or associated gastrointestinal comorbidities may exacerbate mineral metabolism disturbances.

Conservative treatment forms the cornerstone of management and must be individualized based on etiology, severity, and comorbidities. First-line conservative strategies include strict sun exposure guidance (15–30 minutes of midday sunlight on face, arms, and legs, 2–3 times weekly, avoiding peak UV intensity), dietary counseling emphasizing natural sources of vitamin D (fatty fish, egg yolks, fortified dairy and cereals) and bioavailable calcium (low-oxalate leafy greens, tofu set with calcium salts, dairy alternatives), and avoidance of known inhibitors of mineral absorption (e.g., excessive phytates in unfermented grains, high-dose aluminum-containing antacids, or prolonged proton-pump inhibitor use). Physical therapy is integral: supervised, low-impact weight-bearing exercise (e.g., walking, aquatic therapy, resistance band training) improves muscle strength, reduces fall risk, enhances bone mechanotransduction, and mitigates secondary deconditioning. Gait assessment and orthotic support (e.g., custom foot orthoses or temporary bracing for pelvic girdle instability) are routinely incorporated to prevent stress fractures and progressive deformity. Nutritional screening—including serum 25-hydroxyvitamin D, intact parathyroid hormone (iPTH), serum calcium, phosphorus, alkaline phosphatase (ALP), creatinine, and urinary calcium excretion—is mandatory before initiating therapy and repeated at 3–6 month intervals during titration.

Pharmacotherapy is initiated when conservative measures are insufficient or when biochemical deficits are severe. For nutritional vitamin D deficiency (serum 25(OH)D < 20 ng/mL), high-dose cholecalciferol (vitamin D3) is preferred: 50,000 IU weekly for 8 weeks, followed by maintenance dosing of 800–2000 IU daily, adjusted per follow-up levels. In patients with malabsorption (e.g., celiac disease, post-bariatric surgery), calcifediol (25-hydroxyvitamin D) 0.5–1.0 mg daily may be used due to its bypass of hepatic hydroxylation. For renal osteodystrophy or chronic kidney disease–mineral and bone disorder (CKD-MBD), active vitamin D analogs (calcitriol or paricalcitol) are prescribed cautiously under nephrology-rheumatology co-management, with close monitoring of serum calcium and phosphate to avoid hypercalcemia or vascular calcification. Hypophosphatemic osteomalacias require oral phosphate supplementation (e.g., neutral phosphate salts, 25–50 mmol elemental phosphorus daily in divided doses) combined with active vitamin D analogs to counteract FGF23-mediated phosphaturia; in X-linked hypophosphatemia, burosumab—a monoclonal antibody targeting FGF23—is increasingly utilized off-label or within clinical trials in China, pending broader regulatory approval. Bisphosphonates are contraindicated in active osteomalacia, as they further impair mineralization; their use should only be considered after full biochemical and histological resolution.

Surgical intervention is rarely indicated but may be necessary in advanced cases with structural compromise. Orthopedic referral is warranted for pathologic insufficiency fractures (e.g., femoral neck, pelvic rami, or vertebral compression fractures) that fail conservative immobilization or demonstrate progressive deformity. Intramedullary nailing or dynamic hip screw fixation may be employed for unstable proximal femoral fractures. In severe, refractory cases with disabling pelvic pseudofractures (Looser’s zones) or progressive bowing deformities, corrective osteotomy with internal fixation may be performed—typically deferred until biochemical parameters have normalized for ≥6 months to ensure optimal bone healing. Preoperative optimization includes achieving serum 25(OH)D > 30 ng/mL, calcium > 8.5 mg/dL, and phosphorus > 3.0 mg/dL; intraoperative neuromuscular monitoring is advised given potential subclinical myopathy.

Treatment advantages in China include integrated multidisciplinary care pathways within tertiary rheumatology centers, where endocrinologists, nephrologists, gastroenterologists, and rehabilitation specialists collaborate in dedicated Bone Metabolism Clinics. Advanced diagnostic capabilities—such as high-resolution peripheral quantitative computed tomography (HR-pQCT), bone turnover marker panels (PINP, β-CTX), and transiliac bone biopsy with double tetracycline labeling—are increasingly accessible in major academic hospitals (e.g., Peking Union Medical College Hospital, Shanghai Renji Hospital). Moreover, China’s national health insurance system now covers first-line vitamin D formulations and select phosphate binders, significantly improving adherence. Traditional Chinese Medicine (TCM) adjuncts—such as Bu Shen Zhuang Gu Tang (a kidney-tonifying, bone-strengthening decoction)—are evidence-informed and often integrated under dual supervision, with emerging RCT data supporting synergistic effects on ALP normalization and pain reduction when combined with conventional therapy.

Recovery advice emphasizes longitudinal vigilance: patients should undergo annual dual-energy X-ray absorptiometry (DXA) with vertebral fracture assessment (VFA), repeat biochemical profiling every 6 months for the first 2 years, and lifelong surveillance for recurrence—particularly during pregnancy, lactation, or initiation of new immunosuppressants. Fall prevention education, home safety evaluation, and smoking cessation counseling are standard. Patients must understand that symptom improvement (e.g., reduced bone pain, improved proximal muscle strength) typically begins within 4–8 weeks, but full histomorphometric recovery requires 6–12 months. Adherence to prescribed regimens—not intermittent 'vitamin D boosting'—is critical. Finally, family screening is recommended for suspected hereditary forms, and genetic counseling should be offered where appropriate. With timely, etiology-directed intervention, the prognosis for osteomalacia is excellent, with near-complete functional and structural recovery achievable in the majority of cases.